Stay updated with breaking news from Program For Tapinarof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis - Tapinarof was well-tolerated
- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical
Patients from PSOARING 3 who completed the survey preferred tapinarof to prior topical treatments with 81.7% considering it more effective Dermavant Sciences, a clinical-stage biopharmaceutical company
- Patient satisfaction results from tapinarof long-term extension study for the treatment of plaque psoriasis in adults to be presented - Dermavant Sciences, a clinical-stage biopharmaceutical company
(0) - Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance - - A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle - - Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle - - Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 - Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its t...